Exhibit
10.64


AGREEMENT
BY AND BETWEEN ZANDER THERAPEUTICS, INC. AND THOMAS DONNELLY


 


 


 


Agreement
made on August 7, 2017 ("Execution Date") by and between Thomas Donnelly ("Consultant"), a natural person
whose address is at 44 Rue Bourgelat, 94700 Maisons-Alfort, FRANCE and Zander Therapeutics, Inc. ("Company"), a Nevada
corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company may be referred to
individually as "Party" and collectively as "Parties".


It
is agreed as follows:


 


	 	1.	SCOPE
    OF SERVICES


 


Consultant
shall advise client on various nominal matters regarding veterinary biotechnology for the Company's wholly owned subsidiary Zander
Therapeutics Inc. ''Nominal" is defined as periodic conversations in which Consultant is asked for a referral to an appropriate
researcher on a specific topic or input on research data the company is developing. In the event Consultant is requested to provide
research services, such services will be negotiated separately between Consultant and the Company.


 


	 	2.	TERM


 


The
Term of this Agreement shall commence on August 17, 2017 and shall expire on August 16, 2018. The term of this Agreement may be
extended by mutual agreement.


 


	 	3.	INDEPENDENT
    CONTRACTOR


 


The
Parties are independent contractors. Nothing in this Agreement shall be deemed to constitute a partnership or joint venture between
the Parties or constitute any Party to be the agent of the other Party for any purpose.


	 	4.	NON-DISCLOSURE


 


(a)  
All information, whether in oral, written, graphic,
electronic or other form, disclosed by the Company to the Consultant shall be deemed to be "Proprietary Information."
In particular, Proprietary Information includes, without limitation, any trade secrets, confidential information, ideas, inventions
or research and development information; matters of a technical nature, including technology; notes, products, know- how, engineering
or other data (including test data and data files); specifications, processes, techniques, formulae or work-in-process; manufacturing,
planning or marketing procedures, clinical data and regulatory strategies or information; accounting, financial or pricing procedures
or information, budgets or projections, or personnel or salary structure/compensation information; information regarding suppliers,
clients, customers, employees, contractors, investors or investigators of the Company, information which has been designated in
writing as confidential by the Company; programs, procedures (including operating procedures), processes, methods, guidelines,
policies, proposals or contracts; computer software, data bases or programming; and any other information which, if divulged to
a third party, could have an adverse impact on the Company, or on any third party to which it owes a confidentiality obligation.
In addition, "Proprietary Information" includes any of the foregoing relating to


	 	1	 




    	 



    	 



    

 


the
past, present or future operations, organization, projects, finances, business interests, methodology or affairs of any third
party to which the Company owes a duty of confidentiality including, without limitation, the mere fact that the Company is or
may be working with or for any client.


	 	(b)	The
    obligations of confidentiality shall not apply to any Proprietary Information that was known by the Consultant at the time
    of disclosure to it by such Company, or that is independently developed or discovered by the Consultant after disclosure by
    such Company, without the aid, application or use of any item of such Company's Proprietary Information, as evidenced by written
    records; now, or subsequently becomes, through no act or failure to act on the part of the Consultant, generally known or
    available; is disclosed to the Consultant by a third party authorized to disclose it; or is required by law or by court or
    administrative order to be disclosed; provided, that the Consultant shall have first given prompt notice to such Company of
    such required disclosure.


 


	 	(c)	Consultant
    shall exercise due care to prevent the unauthorized use or disclosure of the Company's Proprietary Information, and shall
    not, without the Company's prior written consent, disclose or otherwise make available, directly or indirectly, any item of
    the Company's Proprietary Information to any person or entity other than those employees, independent contractors or agents
    of the Consultant (collectively, "Representatives"), to the extent such Representatives reasonably need to know
    the same in order to evaluate such Proprietary Information, to participate in the business relationship between the parties,
    or to make decisions or render advice in connection therewith. Consultant shall advise its Representatives who have access
    to the Company's Proprietary Information of the confidential and proprietary nature thereof, and agrees that such Representatives
    shall be bound by terms of confidentiality and restrictions on use with respect thereto that are at least as restrictive as
    the terms of this Agreement.


 


	 	(d)	Consultant
    shall exercise due care to prevent the unauthorized use or disclosure of the Company's Proprietary Information, and shall
    not, without the Company's prior written consent, disclose or otherwise make available, directly or indirectly, any item of
    the Company's Proprietary Information to any person or entity other than those employees, independent contractors or agents
    of the Consultant (collectively, "Representatives"), to the extent such Representatives reasonably need to know
    the same in order to participate in any business relationship between the parties, or to make decisions or render advice in
    connection therewith. Consultant shall advise its Representatives who have access to the Company's Proprietary Information
    of the confidential and proprietary nature thereof, and agrees that such Representatives shall be bound by terms of confidentiality
    and restrictions on use with respect thereto that are at least as restrictive as the terms of this Agreement.


 


	 	(e)	Consultant
    shall use the Company's Proprietary Information solely for the purposes of performing his duties pursuant to this Agreement
    and shall not make any other use of the Company's Proprietary Information without the Company's specific written authorization.


 


	 	(f)	All
    Proprietary Information of the Company (including all copies thereof) shall be and at all times remain the property of such
    Company, and all non-oral Proprietary Information of the Company which is then in the Consultant's possession or control shall
    be destroyed or returned to the Company promptly upon its request at any time, and in any event, no later than 60 days following
    any expiration or termination of this Agreement.


 


	 	(g)	Nothing
    in this Agreement shall be construed, by implication or otherwise, as a grant of any right or Iicense to trademarks, inventions,
    copyrights or patents, as a grant of a license to either Consultant to use any of the Company's Proprietary Information except
    as expressly set forth herein.


 


	 	2	 




    	 



    	 



    

 


	 	(h)	The
    provisions of Section 4 of this Agreement shall survive until such time as all Confidential Information disclosed hereafter
    becomes publically known and made generally available through no action or inaction of Consultant.


 


	 	5.	CONSIDERATION


 


 


As
consideration of the performance of services pursuant to this Agreement, Consultant shall receive:


 


	 	(1)	Within
    15 business days ofthe execution date of this Agreement Consultant shall be issued 500,000 shares of the Zander Therapeutics
    Inc.'s Series M Preferred Stock of the Company ("Compensation Shares").


 


	 	(2)	Consultant
    acknowledges that, in the event that a Zander Registration Statement is filed with the United States Securities and Exchange
    Commission ("SEC"), no assurance is given that the Zander Registration Statement will be declared effective by the
    SEC.


 


	 	(3)	Consultant
    acknowledges that any securities issued pursuant to this Agreement that are not registered pursuant to the Securities Act
    of 1933 shall constitute "restricted securities" as that term is defined in Rule 144 promulgated under the Securities
    Act of 1933, and shall contain the following restrictive legend:


 


THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.


 


	 	6.	REPRESENTATIONS
    AND WARRANTIES OF COMPANY


 


(a) 
Company is a corporation duly organized, validly
existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority
to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation
to notify, any person, entity or governmental agency which consent has not been obtained.


 


(b)
The execution, delivery and performance of this
Agreement by Company does not and shall not constitute Company's breach of any statute or regulation or ordinance of any governmental
authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of
any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which Company is
or may be bound.


	 	3	 




    	 



    	 



    

 


 


	 	7.	REPRESENTATIONS
    AND WARRANTIES OF CONSULTANT


 


(a) 
Consultant has the requisite power and authority
to enter into and perform his obligations under this Agreement without the consent, approval or authorization of, or obligation
to notify, any person, entity or governmental agency which consent has not been obtained.


 


(b)
The execution, delivery and performance of this
Agreement by Consultant does not and shall not constitute Consultant's breach of any statute or regulation or ordinance of any
governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or
provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Consultant is a party, or by
which Company is or may be bound.


 


	 	8.	NON-DISPARAGEMENT


 


Consultant
agrees that Consultant shall not, during the term of this Agreement, disparage the Company, the Company's products, the Company's
employees, or members of the Company's board of directors. For purposes of this Agreement the term "disparage" shall
mean any negative comment, written or oral, about the Company, the Company's products, the Company's employees, or members of
the Company's board of directors.. Nothing set forth in this Agreement shall prohibit or limit in any way a Party's right to accurately
and honestly respond as required or to cooperate with any valid government, court or regulatory order or request. The provisions
of Section 8 of this Agreement shall survive until that date which is three years subsequent to the end of the Term of this Agreement.


 


 


	 	9.	WORK
    PRODUCT


 


Consultant
agrees that the Company is the sole and exclusive owner of all intellectual property, including copyrights, trademarks, patents,
inventions, work product and know-how, which may result from any work performed by the Consultant pursuant to this Agreement.
Consultant agrees that Consultant shall, upon request of the Company, execute, acknowledge, deliver and file any and all documents
necessary or useful to vest in the Company all of Consultant's right, title and interest in and to all intellectual property,
including copyrights, trademarks, patents, inventions, work product and know-how, which may result from any work performed by
the Consultant pursuant to this Agreement. The term "Inventions" means all original works of authorship, developments,
concepts, improvements or trade secrets, whether or not patentable under law, that Consultant may individually or jointly conceive
or develop or reduce to practice, or cause to be conceived or developed or reduced to practice.


 


 


	 	10.	SPECIFIC
    PERFORMANCE


 


Any
breach of this Agreement may result in irreparable damage to Company for which Company will not have an adequate remedy at law.
Accordingly, in addition to any other remedies and damages available,


	 	4	 




    	 



    	 



    

 


Consultant
acknowledges and agrees that Company may immediately seek enforcement of this Agreement by means of specific performance or injunction,
without any requirement to post a bond or other security.


 


11.   
EXECUTION


 


This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same Agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.


 


12.   
ENTIRE AGREEMENT


 


 


This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.


 


	 	13.	SEVERABILITY


 


If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate
such substitute provision in this Agreement


 


14. 
GOVERNING LAW, VENUE, WAIYER OF JURY TRIAL


 


All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall


	 	5	 




    	 



    	 



    

 


commence
an action
or
proceeding
to
enforce
any
provisions
of this
Agreement,
then
the prevailing
party in such
action
or
proceeding
shall
be reimbursed
by the
other
party for its attorneys' fees
and other
costs and
expenses
incurred
with
the investigation,
preparation
and
prosecution
of such
action
or proceeding.


 


 


IN
WITN
ESS WH
EREOF, the
parties
hereto
have
caused
this Agreement
to be
duly
executed
by
their



respective
authorized
signatories
as of the
date
first
indicated
above.


 


	COMPANY	 	CONSULTANT
	 	 	 
	By:
    Harry Lander, Ph.D.	 	By:
    Thomas Donnelly
	/s/
    Harry Lander	 	/s/
    Thomas Donnelly
	 	 	 
	lts:
    President and CSO	 	 
	Date:
    August 17, 2017	 	Date:
    August 17, 2017